General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises on Evotec SE’s Public Offering of American Depositary Shares

November 4, 2021
Cross-border team from the US and Germany represents the underwriters in the offering by the drug discovery and development partner for the pharmaceutical and biotechnology industry.

Evotec SE’s (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) management board today decided – with the approval of its supervisory board – on the volume and the issue price of its public offering of American Depositary Shares (ADSs). The offering will produce gross proceeds of US$435,000,000 from the sale of 10,000,000 ordinary shares of Evotec in the form of 20,000,000 ADSs at a price of US$21.75 per ADS. Each ADS will represent one half of an ordinary share of Evotec. Accordingly, Evotec's share capital, on the basis of Evotec’s articles of association, will be increased to €173,914,741,00 by issuing 10,000,000 shares from the authorized capital under exclusion of subscription rights of the existing shareholders (taking into account the subscription shares issued to date from conditional capital, the actual share capital will then amount to €175,110,695). In addition, Evotec has granted the underwriters an option exercisable for 30-days after the date hereof to purchase up to 3,000,000 additional ADSs. The ADSs are expected to begin trading on the Nasdaq Global Select Market on or about November 4, 2021 under the ticker symbol EVO. The offering is expected to close on or about November 8, 2021, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a US corporate team led by New York partners Nathan Ajiashvili and Alison Haggerty, with New York associates Roger Yarett and James Dorian, and a German corporate team led by Frankfurt partner Oliver Seiler, with Frankfurt associates Camilla Kehler-Weiss and Alexandre Maturana.


    Related Capabilities